Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.37
-0.27 (-3.13%)
At close: Aug 28, 2026, 4:00 PM EDT
8.53
+0.16 (1.91%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
149
Market Cap
517.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Editas Medicine | 47.01M |
| Scribe Therapeutics | 36.28M |
| C4 Therapeutics | 35.04M |
| Evommune | 10.00M |
| Ovid Therapeutics | 1.58M |
| ProKidney | 818.00K |
| Artiva Biotherapeutics | 251.00K |
| Entera Bio | 42.00K |
KYTX News
- 18 days ago - Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c) - TheFly
- 18 days ago - Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - Kyverna Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - Kyverna Therapeutics Quarterly report: Q2 2026 - Filings
- 18 days ago - Kyverna Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement - TheFly
- 4 weeks ago - Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer - TheFly